Incretin-based pharmacotherapy and risk of adverse pancreatic events in the ethnic Chinese with diabetes mellitus: A population-based study in Taiwan

Tseng, Chao‐Ming; Liao, Wei‐Chih; Chang, Chi‐Yang; Lee, Ching‐Tai; Hsu, Yao‐Chun; Lin, Jaw–Town

doi:10.1016/j.pan.2016.10.003

Cited by 20 publications

(21 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Several observational studies based on large health care databases have examined the association between DPP-4I and acute pancreatitis. Most of the observational studies found no increased risk of acute pancreatitis associated with DPP-4I (10)(11)(12)(13)(14)(15)(16)(17)(18)(19)(20)(21), whereas three have reported positive associations (22)(23)(24). No study has specifically investigated older Americans and subgroups of patients, including the impact of prior CVD on the association of DPP-4I with acute pancreatitis.…”

mentioning

confidence: 99%

The Risk of Acute Pancreatitis After Initiation of Dipeptidyl Peptidase 4 Inhibitors: Testing a Hypothesis of Subgroup Differences in Older U.S. Adults

et al. 2018

View full text Add to dashboard Cite

show abstract

mentioning

confidence: 99%

The Risk of Acute Pancreatitis After Initiation of Dipeptidyl Peptidase 4 Inhibitors: Testing a Hypothesis of Subgroup Differences in Older U.S. Adults

et al. 2018

View full text Add to dashboard Cite

show abstract

“…Data on relatively new ADMs, incretin-based analogues, is sparse, with conflicting findings and no clear association [7–9]. Although, results of current epidemiological studies suggest a relationship between ADM use and PDAC risk, these data should be inferred with caution.…”

Section: Pdac Risk and Anti-diabetic Medicationsmentioning

confidence: 99%

Pancreatic Cancer and Diabetes Mellitus

Sharma

Chari

2018

Curr Treat Options Gastro

View full text Add to dashboard Cite

Studies report that while some anti-diabetic medications (e.g., metformin) may decrease the risk of PDAC, others (insulin, sulfonylureas and incretin-based therapies) may increase the risk. However, these observations may be subject to protopathic biases. Metformin's anti-tumor activity may have influence overall survival of PDAC, but epidemiological reports have largely been inconsistent to defend these findings due to heterogeneous methodologies. There is congruent data to support the association between DM and PDAC, with an inverse relationship to DM duration. Older subjects with new-onset DM are the only known high-risk group for PDAC, and strategy using this group for early detection has led to development of clinical risk prediction models that define a very high-risk PDAC group. Role of anti-diabetic medication in PDAC risk modification or survival is controversial. With successful efforts to distinguish type 2-DM from PDAC-DM using risk-stratifying models, there is an opportunity to initiate screening protocols for early detection of PDAC in a sub-set of DM subjects.

show abstract

“…The well‐established benefit‐risk profile of DPP‐4 inhibitors however, has been challenged because of safety concerns regarding adverse pancreatic events (acute pancreatitis, pancreatic cancer) which was initially raised by postmarketing surveillance reports from the Food and Drug Administration Adverse Event Reporting System . While some noninterventional studies or meta‐analyses of randomized controlled trials (RCTs) reported an increased risk of pancreatic events, other studies did not find an increased risk …”

Section: Introductionmentioning

confidence: 99%

Pancreatic safety of vildagliptin in patients with type 2 diabetes mellitus: A European, noninterventional, postauthorization safety study

Williams

Kothny

Serban

et al. 2019

Endocrino Diabet & Metabol

View full text Add to dashboard Cite

This cohort study assessed the pancreatic safety of vildagliptin versus other noninsulin antidiabetic drugs (NIADs) based on data from five European electronic health care databases. Patients with type 2 diabetes aged ≥18 years on NIAD treatment were enrolled. Adjusted incidence rate ratios (IRRs) and 95% confidence intervals (CIs) were estimated separately for acute pancreatitis and pancreatic cancer for vildagliptin (± other NIADs) compared with other NIADs using negative binomial regression. Approximately 2.8% of the enrolled patients (n = 738 054) used vildagliptin during the study, with an average follow‐up time of 1.4 years. For acute pancreatitis, adjusted IRRs ranged between 0.89 andt 2.58 with all corresponding 95% CIs crossing 1. For pancreatic cancer adjusted IRRs ranged from 0.56 to 3.64, with the lower limit of 95% CIs >1 in some analyses. Post hoc sensitivity analyses taking latency time into account markedly lowered the risk estimates with corresponding 95% CIs crossing 1. Overall, the results do not suggest an increased pancreatitis risk with vildagliptin, while the observation for pancreatic cancer have to be interpreted carefully as this study was not designed to assess pancreatic cancer and rather be explained by certain underlying limitations including latency ‐time, chance findings and/or bias and confounding.

show abstract

Incretin-based pharmacotherapy and risk of adverse pancreatic events in the ethnic Chinese with diabetes mellitus: A population-based study in Taiwan

Cited by 20 publications

References 26 publications

The Risk of Acute Pancreatitis After Initiation of Dipeptidyl Peptidase 4 Inhibitors: Testing a Hypothesis of Subgroup Differences in Older U.S. Adults

The Risk of Acute Pancreatitis After Initiation of Dipeptidyl Peptidase 4 Inhibitors: Testing a Hypothesis of Subgroup Differences in Older U.S. Adults

Pancreatic Cancer and Diabetes Mellitus

Pancreatic safety of vildagliptin in patients with type 2 diabetes mellitus: A European, noninterventional, postauthorization safety study

Contact Info

Product

Resources

About